Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977720> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4308977720 endingPage "vii73" @default.
- W4308977720 startingPage "vii72" @default.
- W4308977720 abstract "Abstract BACKGROUND 5-ALA SDT is not a blood-brain barrier disruption technique, but rather a first-in-class drug-device therapy exploiting the heme synthesis pathway in recurrent glioblastoma (rGBM). Following IV 5-ALA administration, aberrant tumor metabolism results in protoporphyrin-IX (PpIX) accumulation. Activation of PpIX by non-invasive, non-ablative magnetic resonance-guided focused ultrasound (MRgFUS) induces reactive oxygen species and tumor cell death. This first-in-human Phase 0/1 study investigates the feasibility, safety, and biological effects of 5-ALA SDT in rGBM patients. METHODS Six hours prior to SDT, adult patients with rGBM were administered 10mg/kg of an IV formulation of 5-ALA (SONALA-001). Patients were assigned to one of three ascending acoustic energy levels of MRgFUS (200J/400J/800J, measured at transducer surface), followed by a four-day interval prior to planned tumor resection. In each patient, 50% of the enhancing and nonenhancing tumor volume was targeted with MRgFUS with the untreated tumor serving as an internal control. The Optimal Biological Dose (OBD) associated with 5-ALA SDT is the energy level associated with greatest tumor cell death. RESULTS 8 patients were accrued across all energy levels, and none demonstrated drug- or device-related adverse events. Compared to internal control tissue, the apoptosis biomarker, cleaved caspase-3, was elevated in all patients, but most prominently at the 200J energy level. The oxidative stress biomarkers 4-hydroxynonenal, glutathione, cysteine, and thiol were elevated in treated vs. control tissues at all energy levels. The mean Cmax for 5-ALA and PpIX in plasma were 305 µM and 65 nM, respectively. No off-target histological or radiographic alterations were detected in any patient. CONCLUSIONS This first-in-human Phase 0/1 study of a new therapeutic modality for rGBM patients demonstrates that 5-ALA SDT is safe at 200 to 800J and likely induces targeted cell death in rGBM patients via oxidative stress. At 10mg/kg of 5-ALA, the OBD is at or lower than 200J." @default.
- W4308977720 created "2022-11-20" @default.
- W4308977720 creator A5004840229 @default.
- W4308977720 creator A5006600861 @default.
- W4308977720 creator A5010318779 @default.
- W4308977720 creator A5016104179 @default.
- W4308977720 creator A5020774269 @default.
- W4308977720 creator A5033226431 @default.
- W4308977720 creator A5038635994 @default.
- W4308977720 creator A5064497380 @default.
- W4308977720 creator A5078653239 @default.
- W4308977720 creator A5080631945 @default.
- W4308977720 creator A5081352346 @default.
- W4308977720 creator A5083325281 @default.
- W4308977720 creator A5087190903 @default.
- W4308977720 creator A5091176747 @default.
- W4308977720 creator A5067092120 @default.
- W4308977720 date "2022-11-01" @default.
- W4308977720 modified "2023-10-14" @default.
- W4308977720 title "CTNI-13. A FIRST-IN-HUMAN PHASE 0/1 TRIAL OF 5-AMINOLEVULINIC ACID SONODYNAMIC THERAPY (5-ALA SDT) IN RECURRENT GLIOBLASTOMA" @default.
- W4308977720 doi "https://doi.org/10.1093/neuonc/noac209.279" @default.
- W4308977720 hasPublicationYear "2022" @default.
- W4308977720 type Work @default.
- W4308977720 citedByCount "0" @default.
- W4308977720 crossrefType "journal-article" @default.
- W4308977720 hasAuthorship W4308977720A5004840229 @default.
- W4308977720 hasAuthorship W4308977720A5006600861 @default.
- W4308977720 hasAuthorship W4308977720A5010318779 @default.
- W4308977720 hasAuthorship W4308977720A5016104179 @default.
- W4308977720 hasAuthorship W4308977720A5020774269 @default.
- W4308977720 hasAuthorship W4308977720A5033226431 @default.
- W4308977720 hasAuthorship W4308977720A5038635994 @default.
- W4308977720 hasAuthorship W4308977720A5064497380 @default.
- W4308977720 hasAuthorship W4308977720A5067092120 @default.
- W4308977720 hasAuthorship W4308977720A5078653239 @default.
- W4308977720 hasAuthorship W4308977720A5080631945 @default.
- W4308977720 hasAuthorship W4308977720A5081352346 @default.
- W4308977720 hasAuthorship W4308977720A5083325281 @default.
- W4308977720 hasAuthorship W4308977720A5087190903 @default.
- W4308977720 hasAuthorship W4308977720A5091176747 @default.
- W4308977720 hasBestOaLocation W43089777201 @default.
- W4308977720 hasConcept C126322002 @default.
- W4308977720 hasConcept C142724271 @default.
- W4308977720 hasConcept C143998085 @default.
- W4308977720 hasConcept C178790620 @default.
- W4308977720 hasConcept C181199279 @default.
- W4308977720 hasConcept C185592680 @default.
- W4308977720 hasConcept C197934379 @default.
- W4308977720 hasConcept C204787440 @default.
- W4308977720 hasConcept C2776151105 @default.
- W4308977720 hasConcept C2778448707 @default.
- W4308977720 hasConcept C2779671804 @default.
- W4308977720 hasConcept C2781323092 @default.
- W4308977720 hasConcept C502942594 @default.
- W4308977720 hasConcept C538909803 @default.
- W4308977720 hasConcept C55493867 @default.
- W4308977720 hasConcept C71924100 @default.
- W4308977720 hasConcept C98274493 @default.
- W4308977720 hasConceptScore W4308977720C126322002 @default.
- W4308977720 hasConceptScore W4308977720C142724271 @default.
- W4308977720 hasConceptScore W4308977720C143998085 @default.
- W4308977720 hasConceptScore W4308977720C178790620 @default.
- W4308977720 hasConceptScore W4308977720C181199279 @default.
- W4308977720 hasConceptScore W4308977720C185592680 @default.
- W4308977720 hasConceptScore W4308977720C197934379 @default.
- W4308977720 hasConceptScore W4308977720C204787440 @default.
- W4308977720 hasConceptScore W4308977720C2776151105 @default.
- W4308977720 hasConceptScore W4308977720C2778448707 @default.
- W4308977720 hasConceptScore W4308977720C2779671804 @default.
- W4308977720 hasConceptScore W4308977720C2781323092 @default.
- W4308977720 hasConceptScore W4308977720C502942594 @default.
- W4308977720 hasConceptScore W4308977720C538909803 @default.
- W4308977720 hasConceptScore W4308977720C55493867 @default.
- W4308977720 hasConceptScore W4308977720C71924100 @default.
- W4308977720 hasConceptScore W4308977720C98274493 @default.
- W4308977720 hasIssue "Supplement_7" @default.
- W4308977720 hasLocation W43089777201 @default.
- W4308977720 hasOpenAccess W4308977720 @default.
- W4308977720 hasPrimaryLocation W43089777201 @default.
- W4308977720 hasRelatedWork W1996833785 @default.
- W4308977720 hasRelatedWork W2007226354 @default.
- W4308977720 hasRelatedWork W2030013026 @default.
- W4308977720 hasRelatedWork W2038832028 @default.
- W4308977720 hasRelatedWork W2052449390 @default.
- W4308977720 hasRelatedWork W2131763938 @default.
- W4308977720 hasRelatedWork W2463171293 @default.
- W4308977720 hasRelatedWork W2467060560 @default.
- W4308977720 hasRelatedWork W3120735659 @default.
- W4308977720 hasRelatedWork W4252057958 @default.
- W4308977720 hasVolume "24" @default.
- W4308977720 isParatext "false" @default.
- W4308977720 isRetracted "false" @default.
- W4308977720 workType "article" @default.